Logo

EUDA

EUDA Health Holdings Limited

EUDA

EUDA Health Holdings Limited • NASDAQ
$3.12 ▲ 6.12% (+0.18)
Market Cap $115.00 M
52w High $6.30
52w Low $1.03
Dividend Yield 0%
P/E 156
Volume 33.02K
Outstanding Shares 36.86M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $1.529M $983.746K $-602K -39.381% $-0.016 $-519.324K
Q1-2025 $1.529M ▲ $983.746K ▲ $-602K ▼ -39.381% ▼ $-0.016 ▼ $-519.324K ▼
Q4-2024 $1.051M $655.098K $735.337K 69.934% $-0.007 ▲ $-476.939K
Q3-2024 $1.051M ▲ $655.098K ▼ $735.337K ▲ 69.934% ▲ $-0.014 ▲ $-476.939K ▲
Q2-2024 $954.024K $8.394M $-8.414M -881.948% $-0.29 $-789K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $176.584K $2.122M $5.849M $-3.71M
Q1-2025 $176.584K ▼ $2.122M ▲ $5.849M ▲ $-3.71M ▼
Q4-2024 $237.605K $1.698M ▲ $4.27M ▲ $-2.553M ▲
Q3-2024 $237.605K ▼ $1.698M ▼ $4.27M ▼ $-2.553M ▲
Q2-2024 $376.206K $2.028M $8.039M $-6.023M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-602K $-607.712K $-11.611K $558.879K $0 $-619.323K
Q1-2025 $-602K ▼ $-607.712K ▼ $-11.611K ▲ $558.879K ▲ $0 $-619.323K ▼
Q4-2024 $735.337K $-388.065K $-71.872K $413.343K $0 ▲ $-435.87K
Q3-2024 $735.337K ▲ $-388.065K ▲ $-71.872K ▼ $413.343K ▼ $-390.578K ▼ $-435.87K ▲
Q2-2024 $-8.414M $-629.299K $-2.011K $748.757K $390.578K $-629.875K

Revenue by Products

Product Q1-2023
Medical Service
Medical Service
 $0 ▲
Property Management Services
Property Management Services
 $0 ▲

Five-Year Company Overview

Income Statement

Income Statement EUDA looks like a very early‑stage, mostly pre‑revenue company. Over the last several years, it has reported essentially no meaningful sales but has still been spending on operations, which shows up as recurring losses. Earnings per share have swung from a small profit in the SPAC listing period to ongoing, modest but persistent losses since. In plain language: the business model is still in the build‑out phase. The company is investing ahead of revenue, and the core healthcare platform and wellness offerings have not yet translated into a clear, stable revenue base. That makes future profitability highly uncertain and heavily dependent on successful execution of its growth plans.

Balance Sheet

Balance Sheet The balance sheet is very thin. Reported total assets are very small, there is essentially no reported cash cushion in the historical data, and no notable debt. At one point, equity dipped slightly negative, which usually signals accumulated losses outweighing the small capital base. This profile is typical of a tiny, early‑stage company that has limited resources to absorb setbacks. It suggests EUDA may need continued external funding or corporate transactions to support its strategy, because the current balance sheet does not provide much financial safety net on its own.

Cash Flow

Cash Flow Reported cash flow figures are effectively flat, with no meaningful operating cash inflows and no visible free cash flow generation. In other words, there is no evidence yet that the business is self‑funding. For a company like this, the key question is not how strong current cash flow is, but whether the pipeline of products, partnerships, and acquisitions can eventually create steady, recurring cash inflows. Until that happens, the company’s ability to raise and manage cash from outside sources remains critical.

Competitive Edge

Competitive Edge Strategically, EUDA is trying to carve out a niche in Southeast Asia and China by blending digital health, wellness, and advanced therapies into one integrated ecosystem. Its pitch is a “one‑stop” platform: an AI‑driven digital front end, combined with physical wellness products and potential hospital‑grade treatments, all aimed at proactive and longevity‑focused care. There are some potential strengths here: a differentiated wellness device (the Bioenergy Capsule), a direct‑to‑consumer wellness channel through acquisitions, and a clear focus on aging populations and preventive care. At the same time, digital health and longevity are crowded, fast‑moving, and highly regulated fields. EUDA is competing against larger, better‑funded players and must prove that its ecosystem can scale, attract users, and gain clinical and regulatory acceptance. Overall, its competitive position today is more about concept and partnerships than about demonstrated market dominance or scale.

Innovation and R&D

Innovation and R&D Innovation is the strongest part of the EUDA story. The company highlights a proprietary AI health platform designed to assess patients quickly, route them to the right care, and predict outcomes. Around this, it is building a suite of unusual wellness and medical offerings: the Bioenergy Capsule with multiple non‑invasive therapies in one device, nutrigenomic supplements aiming at gene expression, and early‑stage work in stem cells, T‑cell therapies, and CRISPR‑based approaches. On top of that, EUDA is exploring joint ventures and acquisitions to gain access to stem cell and induced pluripotent stem cell technologies, and is considering a merger with a U.S. biotech focused on oncology and women’s health. These moves, if completed and validated, could significantly deepen its technology base. However, this is all high‑risk, long‑cycle innovation. Regulatory approvals, clinical validation, manufacturing, and adoption hurdles are substantial. The company’s R&D and deal‑making agenda is ambitious relative to its current size and financial resources, so execution risk is high.

Summary

EUDA is an innovation‑heavy, early‑stage healthcare platform with a bold vision but very limited current financial scale. From the financials, it looks essentially pre‑revenue with ongoing losses, a very small asset base, and no obvious cash‑flow support from operations. That leaves little margin for error and implies a strong dependence on external financing and successful deal execution. From the strategic and innovation side, the story is much more expansive: an AI‑driven digital health platform, a distinctive wellness device network, regenerative medicine ambitions, and targeted expansion across Asia and potentially beyond. If the company can turn these ideas and collaborations into proven products, regulatory approvals, and recurring revenue, its profile could change meaningfully. The key uncertainties are execution, regulatory and clinical validation, funding, and the ability to differentiate in a competitive digital health and longevity landscape. Future milestones to watch include actual commercial traction for its wellness devices and digital platform, progress on stem cell and gene‑based initiatives, the outcome of proposed partnerships and mergers, and any clear shift from concept‑driven to revenue‑driven performance.

NEWS

September 10, 2025 · 9:30 AM UTC

EUDA Signs Letter of Intent to Potentially Acquire GO POSB

Read more